Linzess linaclotide: Phase III started

Ironwood and Actavis began a double-blind, placebo-controlled, U.S. Phase III trial evaluating 72 and 145 Ug oral Linzess once daily for 12 weeks in 1,200 patients. The partners market 145 Ug Linzess in the U.S. for the indication and 290 Ug to treat irritable bowel syndrome with constipation (IBS-C). ...